valu
neg
predict
valu
sensit
assay
significantli
higher
antepartum
cultur
furthermor
mani
clinician
use
riskbas
approach
gb
colon
treat
highrisk
women
empir
antibiot
without
wait
cultur
result
assay
also
significantli
sensit
riskfactor
approach
versu
regard
predict
intrapartum
statu
quick
accur
result
obtain
idistrep
b
assay
labor
suggest
use
would
lead
reduc
rate
neonat
gb
colon
judici
use
antibiot
posit
blood
cultur
result
report
impact
outcom
bsi
st
loui
md
consult
mani
patient
bloodstream
infect
bsi
receiv
adequ
therapi
even
final
microbiolog
report
avail
method
report
microbiolog
inform
physician
signific
impact
whether
inform
use
accord
octob
clinic
infecti
diseas
dr
emilio
bouza
colleagu
hospit
gener
universitario
gregorio
madrid
evalu
data
bsi
microbiolog
result
report
differ
way
case
group
physician
inform
telephon
result
given
written
report
definit
result
known
case
group
b
physician
also
receiv
written
report
bedsid
along
written
therapeut
recommend
case
group
c
physician
also
receiv
clinic
advic
oral
empir
treatment
patient
receiv
inappropri
treatment
receiv
treatment
patient
significantli
longer
hospit
stay
mean
versu
day
higher
risk
clostridium
difficileassoci
diarrhoea
versu
infectionrel
death
versu
allcaus
mortal
versu
patient
whose
empir
therapi
appropri
report
receiv
therapi
chang
patient
group
b
group
c
none
patient
group
consequ
proport
day
patient
receiv
adequ
treatment
significantli
smaller
group
group
b
c
versu
respect
group
also
receiv
significantli
fewer
defin
daili
dose
appropri
antibiot
versu
day
durat
hospit
mortal
rate
report
receiv
cost
also
tend
lower
group
b
c
result
suggest
written
andor
oralalert
report
provid
clinic
advic
addit
standard
report
improv
manag
patient
bsi
dr
lynda
ann
szczech
colleagu
women
interag
hiv
studi
recruit
hivposit
octob
novemb
differ
develop
new
acquir
immunodefici
virusdefin
ill
adi
death
compar
accord
renal
statu
haart
statu
baselin
patient
proteinuria
patient
significantli
lower
lymphocyt
count
higher
viral
load
patient
without
proteinuria
baselin
start
haart
haart
widespread
proteinuria
associ
significantli
increas
risk
develop
new
adi
hazard
ratio
hr
death
hr
elev
creatinin
level
also
signific
independ
risk
factor
mortal
hr
per
decreas
invers
creatinin
level
howev
even
haart
initi
proteinuria
signific
independ
predictor
mortal
hr
elev
creatinin
level
also
signific
predictor
newonset
adi
death
hr
per
decreas
invers
creatinin
level
respect
whether
kidney
modul
hiv
diseas
whether
find
mere
reflect
impact
greater
comorbid
known
clear
howev
hivposit
women
find
need
improv
monitor
aggress
treatment
genet
transmiss
analysi
helicobact
pylori
strain
within
famili
raymond
j
thiberg
jm
chevali
c
kalach
n
bergeret
labign
et
al
look
evid
intrafamili
infect
isol
helicobact
pylori
clone
biopsi
specimen
taken
parent
four
children
compar
sequenc
two
housekeep
gene
hspa
glmm
clone
unrel
strain
patient
live
differ
geograph
region
strain
relationship
within
famili
determin
analyz
allel
variat
loci
build
phylogenet
tree
use
multilocu
sequenc
type
hspaand
glmmbase
phylogenet
tree
show
east
asian
african
branch
sampl
famili
member
show
natur
mix
infect
ident
allel
found
strain
isol
children
parent
strain
isol
unrel
patient
demonstr
strain
circul
within
famili
sever
mechan
point
mutat
intragen
recombin
introduct
foreign
african
allel
shown
enhanc
strain
divers
within
famili
increas
report
appear
novel
nonmultiresist
methicillinresist
staphylococcu
aureu
mrsa
mrsa
strain
commun
spread
hospit
mrsa
strain
commun
caus
public
health
concern
conduct
two
nation
survey
uniqu
isol
aureu
clinic
specimen
collect
nonhospit
patient
commenc
respect
total
isol
isol
mrsa
approxim
mrsa
isol
nonmultiresist
resist
less
three
nine
antibiot
survey
major
multiresist
mrsa
isol
survey
belong
two
strain
strain
determin
pulsedfield
gel
electrophoresi
pfge
resistogram
type
isol
isol
select
multilocu
sequenc
type
mlst
staphylococc
chromosom
cassett
mec
sccmec
analysi
st
sequenc
type
thu
belong
clone
eastern
australian
mrsa
strain
spread
intern
four
predomin
clone
novel
nonmultiresist
mrsa
identifi
pfge
mlst
sccmec
analysi
strain
strain
strain
swp
strain
queensland
last
three
clone
associ
commun
acquisit
total
st
identifi
survey
includ
six
uniqu
clone
novel
nonmultiresist
mrsa
name
st
new
st
sccmec
type
iv
v
present
divers
genet
background
find
provid
support
acquisit
sccmec
multipl
lineag
aureu
also
confirm
hospit
commun
strain
mrsa
common
nonhospit
patient
throughout
australia
use
multipl
nucleic
acid
amplif
test
defin
infectedpati
gold
standard
clinic
trial
new
diagnost
test
chlamydia
trachomati
infect
martin
dh
nsuami
schachter
j
hook
ew
ferrero
quinn
tc
gaydo
c
nucleic
acid
amplif
test
naat
use
defin
infectedpati
gold
standard
purpos
design
studi
perform
chlamydia
trachomati
diagnost
test
unclear
mani
test
result
run
differ
naat
combin
specimen
compris
best
infectedpati
gold
standard
approach
question
data
larg
studi
perform
new
naat
data
avail
three
endocerv
swab
urin
specimen
collect
women
test
three
differ
naat
result
three
assay
use
equal
rotat
fashion
defin
infectedpati
gold
standard
multipl
differ
infectedpati
gold
standard
estim
swab
urin
specimen
sensit
specif
one
naat
method
creat
vari
number
combin
swab
urin
compar
result
two
differ
naat
effect
chang
infectedpati
gold
standard
definit
determin
construct
receiveroperatorlik
curv
calcul
sensit
specif
test
onepositiveoftworesult
twopositiveoftworesult
two
differ
assay
infectedpati
gold
standard
definit
produc
low
sensit
low
specif
estim
respect
four
compar
naat
result
use
anythreepositiveoffourresult
definit
atleastonespecimenpositivebyeachoftwocomparatorassay
definit
appear
provid
better
combin
sensit
specif
estim
anytwopositiveoutofthreeresult
definit
result
estim
good
produc
former
two
definit
analyt
approach
provid
mean
clearli
visual
effect
chang
naatbas
infectedpati
gold
standard
help
design
futur
studi
new
c
trachomati
diagnost
test
prospect
studi
human
metapneumoviru
infect
children
less
year
age
konig
b
konig
w
arnold
r
werchau
h
ihorst
g
forster
j
lower
respiratori
tract
infect
lrti
children
age
year
due
respiratori
syncyti
viru
rsv
epidemiolog
host
viral
factor
eventu
account
sever
lrti
complet
explain
human
metapneumoviru
hmpv
recent
identifi
children
lrti
populationbas
prospect
multicent
studi
pride
studi
conduct
germani
year
test
nasopharyng
secret
children
younger
year
age
lrti
rsv
b
influenza
virus
iv
b
parainfluenza
virus
piv
children
requir
intens
care
hmpv
infect
children
infect
hmpv
combin
rsv
detect
hmpv
randomli
select
subset
rsvposit
nasopharyng
secret
children
requir
intens
care
support
hmpv
detect
virusneg
sampl
patient
without
intens
care
support
data
support
hypothesi
coinfect
rsv
hmpv
sever
infect
either
rsv
hmpv
alon
least
children
younger
year
age
candida
parapsilosi
import
caus
bloodstream
infect
health
care
set
investig
larg
c
parapsilosi
outbreak
occur
commun
hospit
conduct
casecontrol
studi
determin
risk
factor
infect
identifi
case
bloodstream
infect
c
parapsilosi
confirm
possibl
factor
associ
increas
risk
infect
includ
hospit
intens
care
unit
adjust
odd
ratio
confid
interv
receipt
total
parenter
nutrit
adjust
odd
ratio
confid
interv
sampl
surveil
cultur
obtain
health
care
worker
hand
central
venou
cathet
insert
site
medic
devic
twentysix
percent
health
care
worker
survey
demonstr
hand
colon
c
parapsilosi
one
hand
isol
highli
relat
casepati
isol
test
dna
probe
outbreak
strain
isol
also
demonstr
reduc
suscept
fluconazol
voriconazol
largest
known
report
outbreak
c
parapsilosi
bloodstream
infect
adult
result
interplay
host
environ
pathogen
factor
recommend
control
measur
focus
improv
hand
hygien
complianc
heikkinen
silvennoinen
h
peltola
v
ziegler
vainionpaa
r
vuorinen
kainulainen
l
puhakka
jartti
toikka
p
lehtinen
p
routi
juven
background
influenza
vaccin
healthi
children
encourag
children
frequent
hospit
influenzaattribut
ill
howev
children
influenza
treat
outpati
scarc
data
avail
burden
influenza
children
method
perform
prospect
studi
respiratori
infect
preenrol
cohort
children
year
old
consecut
respiratori
season
childseason
followup
sign
respiratori
infect
examin
children
obtain
nasal
swab
detect
influenza
parent
fill
daili
symptom
diari
enrolle
remain
activ
particip
studi
result
averag
annual
rate
influenza
highest
children
among
children
year
old
acut
otiti
media
develop
complic
influenza
children
year
old
everi
influenzainfect
children
year
old
day
parent
work
loss
mean
durat
day
influenza
caus
substanti
burden
ill
outpati
children
famili
vaccin
children
year
old
might
benefici
reduc
direct
indirect
cost
influenza
children
moscicki
ab
ellenberg
jh
crowleynowick
p
darragh
tm
xu
j
fahrat
background
risk
develop
human
papillomaviru
hpv
associ
precanc
highgrad
squamou
intraepitheli
lesion
hsil
human
immunodefici
viru
hiv
infect
adolesc
unknown
examin
risk
develop
hsil
among
adolesc
without
hiv
infect
method
hivinfect
anduninfect
girl
age
year
particip
multicent
studi
primarili
horizont
acquir
hiv
infect
adolesc
reach
excel
adolesc
health
care
hsil
cytolog
examin
studi
entri
first
followup
visit
follow
interv
hivuninfect
girl
recruit
comparison
ratio
hiv
infect
hiv
uninfect
primari
outcom
cytolog
diagnosi
hsil
confirm
expert
review
result
incid
hsil
end
followup
higher
hivinfect
girl
hivuninfect
girl
vs
respect
multivari
analysi
use
hormon
either
estrogenprogesteron
oral
combin
medroxyprogesteron
acet
intramuscular
contracept
high
cervic
mucou
concentr
interleukin
il
posit
hpv
test
persist
lowgrad
squamou
intraepitheli
lesion
lsil
significantli
associ
develop
hsil
conclus
incid
hsil
alarmingli
high
hivinfect
adolesc
girl
howev
predictor
consid
multivari
analysi
hiv
statu
retain
model
heighten
risk
hsil
associ
persist
lsil
underscor
need
close
monitor
hivinfect
adolesc
lsil
risk
hsil
associ
high
concentr
may
suggest
local
immun
dysregul
role
hormon
contracept
risk
factor
deserv
investig
littl
known
epidemiolog
profil
trichomoniasi
men
relationship
human
immunodefici
viru
hiv
infect
among
men
present
care
symptomat
sexual
transmit
infect
sti
malawi
trichomoniasi
consid
firstlin
treatment
method
conduct
crosssect
survey
men
attend
either
dermatolog
sti
outpati
clinic
capit
malawi
men
interview
etiolog
sti
determin
result
sti
clinic
men
identifi
men
trichomona
vaginali
infect
men
hiv
infect
men
neisseria
gonorrhoea
infect
dermatolog
clinic
men
identifi
men
respect
clinic
lower
educ
level
report
never
use
condom
predict
vaginali
infect
dermatolog
clinic
older
age
associ
infect
sti
clinic
marit
genit
ulcer
diseas
hivinfect
statu
associ
vaginali
infect
sti
clinic
urethr
symptom
attribut
trichomoniasi
sever
among
hivposit
men
among
hivneg
men
conclus
given
high
preval
increas
risk
hiv
transmiss
vaginali
infect
reconsid
inclus
malawi
stitreat
regimen
men
pmid
pubmedin
process
role
human
neutrophil
possibl
adjunct
antituberculosi
chemotherapi
kalita
verma
khuller
gk
report
role
human
neutrophil
peptid
hnp
adjunct
antituberculosi
antitb
drug
combin
isoniazid
rifampicin
evalu
mycobacterium
tuberculosi
h
rv
vitro
ex
vivo
vivo
synerg
observ
basi
reduct
minimum
inhibitori
concentr
mic
agent
vitro
result
reveal
unit
reduct
even
antitb
drug
use
mic
combin
also
found
bactericid
intracellular
mycobacteria
even
mic
drug
use
conjunct
antitb
drug
result
signific
clearanc
bacteri
load
lung
liver
spleen
infect
compar
control
anim
effect
therapeut
dosag
drug
could
reduc
half
supplement
therapeut
schedul
result
clearli
suggest
use
adjunct
chemotherapi
convent
drug
tb
phase
iii
trial
dr
joann
h
van
burik
nation
institut
allergi
infecti
diseas
mycos
studi
group
studi
children
adult
undergo
hsct
half
random
receiv
micafungin
mg
mgkg
patient
kg
wherea
other
receiv
fluconazol
mg
mgkg
patient
kg
drug
administ
day
via
infus
neutropen
phase
hsct
ie
engraft
continu
neutropenia
resolv
day
hsct
whichev
came
earlier
fungal
infect
develop
time
treatment
success
also
significantli
shorter
micafungin
excess
toxic
occur
micafungin
compar
fluconazol
fewer
patient
receiv
micafungin
drop
studi
due
drugrel
advers
event
versu
result
suggest
micafungin
effect
altern
fluconazol
antifung
prophylaxi
neutropen
patient
hsct
author
obtain
baselin
blood
sampl
girl
year
old
africanamerican
white
seroposit
cmv
also
assess
year
later
baselin
subject
girl
histori
sexual
activ
proport
increas
girl
followup
overal
seroposit
cmv
increas
seroposit
increas
seroposit
doubl
among
sexual
experienc
girl
seroposit
increas
increas
correspond
attack
rate
case
cmv
per
personyear
case
per
personyear
entir
cohort
among
sexual
experienc
girl
attack
rate
case
per
personyear
sexual
activ
followup
gener
estim
equat
model
identifi
factor
significantli
associ
seroposit
also
save
money
accord
new
studi
dr
kent
k
hu
colleagu
veteran
affair
puget
sound
health
care
system
seattl
wash
institut
discuss
find
novemb
clinic
infecti
diseas
author
develop
decis
analysi
model
base
hospit
patient
like
requir
cvc
day
ie
intens
care
unit
immunosuppress
receiv
total
parenter
nutrit
cvc
insert
accord
either
msb
techniqu
person
insert
cathet
must
wear
head
cap
face
mask
steril
bodi
gown
steril
glove
use
fullsiz
steril
drape
around
site
accord
lessstring
measur
steril
glove
small
region
steril
drape
basecas
analysi
use
msb
actual
lower
cost
compar
lessstring
infect
control
measur
versu
per
cathet
insert
incid
catheterrel
bsi
versu
cathet
colon
versu
death
versu
also
lower
msb
sensit
analyseseven
wide
rang
clinic
econom
assumptionsth
use
msb
result
improv
patient
safeti
data
suggest
improv
manag
infect
use
msb
also
pay
lower
medic
cost
thu
even
though
msb
sometim
cumbersom
time
consum
author
suggest
routin
use
cvc
insert
hypogonad
risk
factor
gynecomastia
hivposit
men
st
loui
md
consult
studi
suggest
antiretrovir
therapi
risk
factor
gynecomastia
men
human
immunodefici
viru
hiv
infect
howev
associ
ever
found
durat
exposur
antiretrovir
drug
develop
gynecomastia
instead
appear
hypogonad
predispos
factor
gynecomastia
hivinfect
men
accord
novemb
clinic
infecti
diseas
dr
alejandra
biglia
colleagu
univers
barcelona
spain
institut
studi
men
hiv
infect
clinic
examin
confirmatori
sonographi
show
men
gynecomastia
similar
preval
gynecomastia
gener
popul
case
match
men
hiv
gynecomastia
clinic
demograph
laboratori
featur
extens
compar
group
mean
free
testosteron
index
significantli
lower
case
control
vs
hypogonad
strongest
independ
predictor
gynecomastia
adjust
odd
ratio
factor
increas
risk
gynecomastia
includ
hepat
c
viru
infect
adjust
lipoatrophi
adjust
furthermor
gynecomastia
resolv
mani
patient
persist
gynecomastia
transderm
intramuscular
testosteron
administr
fact
improv
without
intervent
substanti
proport
men
author
also
compar
antiretrovir
drug
use
case
control
significantli
case
take
stavudin
vs
efavirenz
vs
significantli
control
take
zidovudin
vs
howev
durat
exposur
drug
differ
significantli
case
control
argu
antiretrovir
therapi
caus
gynecomastia
hivposit
men
author
conclud
gynecomastia
hivinfect
men
appear
relat
hypogonad
advers
effect
antiretrovir
therapi
gynecomastia
prove
relat
hypogonad
hormon
treatment
may
abl
revers
lipodystrophi
studi
warrant
clin
infect
di
taira
av
neukerman
cp
sander
gd
human
papillomaviru
hpv
implic
primari
etiolog
agent
cervic
cancer
potenti
vaccin
highrisk
hpv
type
clinic
trial
evalu
vaccin
program
vaccin
develop
diseas
transmiss
model
estim
hpv
preval
infect
rate
popul
overal
age
group
level
sexual
activ
within
age
group
sex
data
base
clinic
trial
publish
unpublish
sourc
vaccin
girl
would
reduc
cohort
cervic
cancer
case
costeffect
ratio
per
qualityadjust
life
year
qali
includ
male
particip
vaccin
rollout
would
reduc
cervic
cancer
case
increment
costeffect
ratio
compar
femaleonli
vaccin
vaccin
costeffect
although
includ
male
particip
vaccin
program
gener
costeffect
compar
femaleonli
vaccin
yoko
ds
noskin
ga
cunningham
sm
zuccotti
g
plaskett
fraser
vj
et
al
evalu
antimicrobi
exposur
discharg
diagnos
identifi
surgic
site
infect
ssi
retrospect
cohort
studi
hospit
involv
weight
random
sampl
record
coronari
arteri
bypass
graft
cabg
procedur
cesarean
deliveri
breast
procedur
compar
routin
surveil
detect
inpati
antimicrobi
exposur
day
cabg
day
cesarean
day
breast
procedur
discharg
diagnos
togeth
method
identifi
ssi
cabg
cesarean
breast
procedur
antimicrobi
exposur
highest
sensit
compar
routin
surveil
diagnosi
code
improv
sensit
detect
antimicrobi
exposur
cesarean
record
review
confirm
ssi
procedur
met
antimicrobi
surveil
criteria
suffici
antimicrobi
exposur
day
togeth
diagnosi
code
cesarean
identifi
postop
ssi
routin
surveil
method
screen
method
effici
readili
standard
suitabl
hospit
miner
al
sand
ke
yoko
ds
freedman
j
thompson
k
livingston
jm
et
al
investig
use
administr
claim
data
identifi
surgic
site
infect
ssi
breast
surgeri
cesarean
section
postop
diagnosi
code
procedur
code
pharmaci
inform
automat
scan
use
identifi
claim
suggest
ssi
indic
among
breast
procedur
cesarean
section
breast
procedur
indic
explain
avail
medic
record
ssi
confirm
infect
criteria
present
anoth
among
cesarean
section
ssi
confirm
criteria
met
extrapol
infect
rate
breast
procedur
cesarean
section
similar
report
nation
nosocomi
infect
surveil
program
differ
repres
predominantli
outpati
infect
claim
data
may
complement
data
sourc
identif
surgic
site
infect
follow
breast
surgeri
cesarean
section
sever
studi
shown
nasopharyng
sampl
sensit
oropharyng
sampl
detect
pneumococc
carriag
children
data
adult
limit
conflict
studi
part
larger
studi
pneumococc
carriag
navajo
white
mountain
apach
reserv
follow
clinic
trial
sevenval
pneumococc
conjug
vaccin
person
age
year
older
live
household
children
enrol
vaccin
trial
elig
collect
nasopharyng
oropharyng
specimen
pass
flexibl
calcium
algin
wire
swab
either
nasal
posterior
nasopharynx
oral
posterior
oropharynx
swab
place
skim
milktryptoneglucoseglycerin
medium
frozen
pneumococc
isol
perform
standard
techniqu
analys
base
specimen
collect
adult
live
household
nasopharyng
specimen
confid
interv
ci
significantli
like
grow
pneumococci
oropharyng
specimen
ci
p
person
pneumococc
growth
specimen
therefor
test
togeth
like
identifi
pneumococc
carriag
ci
either
test
alon
although
found
nasopharyng
sampl
sensit
oropharyng
sampl
nasopharyng
sampl
alon
would
underestim
preval
pneumococc
carriag
adult
popul
sampl
site
may
give
accur
result
sampl
either
site
alon
studi
pneumococc
carriag
adult
microbiol
pmid
pubmedin
process
effect
intrapartum
penicillin
prophylaxi
intestin
bacteri
colon
infant
jaureguy
f
carton
panel
p
foucaud
p
butel
mj
doucetpopulair
f
earlyonset
group
b
streptococc
gb
infect
remain
lead
caus
morbid
mortal
infant
prevent
vertic
transmiss
gb
neonat
gb
infect
guidelin
recommend
intrapartum
penicillin
amoxicillin
prophylaxi
intrapartum
antibiot
prophylaxi
iap
suspect
favor
colon
antibioticresist
bacteria
howev
effect
prophylaxi
pattern
acquisit
gastrointestin
bacteri
flora
infant
never
studi
collect
stool
sampl
infant
born
mother
receiv
intrapartum
amoxicillin
antibioticexpos
group
untreat
mother
nonantibioticexpos
group
group
match
factor
known
affect
intestin
microbi
colon
gestat
age
type
deliveri
type
feed
qualit
quantit
differenti
analys
bacteri
flora
stool
sampl
perform
similar
number
infant
nonantibioticexpos
antibioticexpos
group
colon
aerob
bacteria
amoxicillinresist
enterobacteria
respect
contrast
significantli
fewer
infant
antibioticexpos
group
nonantibioticexpos
group
colon
anaerob
bacteria
especi
clostridium
respect
p
regard
intestin
bacteri
colon
differ
antibioticexpos
nonantibioticexpos
infant
remark
statist
signific
effect
reduc
initi
bacteri
colon
clostridium
antibioticexpos
group
studi
use
iap
favor
colon
betalactamresist
bacteria
howev
evalu
requir
highlight
potenti
risk
widespread
use
antibiot
prevent
earlyonset
gb
infect
microbiol
pmid
pubmedin
process
use
routin
epicardi
pace
wire
cultur
earli
predict
poststernotomi
mediastin
mekontsodessap
honor
kirsch
houel
r
loisanc
brunbuisson
c
poststernotomi
mediastin
psm
one
seriou
complic
cardiac
surgeri
associ
morbid
mortal
demand
earli
recognit
emerg
therapi
studi
investig
use
epicardi
pace
wire
epw
cultur
predict
psm
among
patient
underw
cardiac
surgic
procedur
hospit
januari
decemb
psm
staphylococcu
aureu
organ
frequent
isol
time
surgic
debrid
epw
patient
develop
psm
cultur
epw
cultur
posit
often
coagulaseneg
staphylococci
epw
cultur
truli
posit
case
truli
neg
case
fals
posit
case
fals
neg
case
steril
cultur
case
cultur
posit
organ
differ
isol
time
debrid
case
epw
cultur
posit
predict
valu
high
neg
predict
valu
diagnosi
psm
accuraci
howev
likelihood
ratio
posit
neg
test
indic
small
chang
pretesttoposttest
probabl
therefor
strategi
routin
cultur
epw
predict
psm
seem
question
dualprob
assay
rapid
detect
drugresist
mycobacterium
tuberculosi
realtim
pcr
wada
maeda
tamaru
imai
hase
kobayashi
k
mutat
particular
nucleotid
gene
code
drug
target
drugconvert
enzym
lead
drug
resist
mycobacterium
tuberculosi
rapid
detect
drugresist
tuberculosi
clinic
specimen
simpl
applic
method
need
eight
taqman
minor
groov
binder
mgb
probe
discrimin
onebas
mismatch
design
dualprob
assay
four
reaction
tube
target
six
mgb
probe
rpob
gene
involv
rifampin
resist
five
probe
design
detect
mutat
site
within
hot
spot
rpob
gene
one
probe
design
tuberculosi
tb
control
outsid
rpob
gene
hotspot
also
design
probe
examin
codon
katg
codon
embb
mutat
associ
resist
isoniazid
ethambutol
respect
system
tuberculosi
complex
specif
neither
nontubercul
mycobacteria
bacteria
mycobacteria
react
system
detect
limit
direct
preamplifi
analys
fg
genom
dna
respect
system
could
detect
mutat
rpob
katg
embb
gene
dna
extract
laboratori
strain
sputum
sampl
patient
pulmonari
tb
system
much
faster
h
dna
prepar
convent
drug
suscept
test
week
result
dualmgbprob
assay
consist
dna
sequenc
dualprob
assay
system
simpl
rapid
accur
appli
detect
drugresist
tuberculosi
clinic
laboratori
defin
methicillinresist
staphylococcu
aureu
mrsa
reservoir
commun
popul
dynam
studi
molecular
epidemiolog
random
sampl
collect
inpati
outpati
mrsa
isol
period
san
francisco
note
progress
replac
type
ii
staphylococc
chromosom
cassett
scc
mecbear
isol
type
iv
sccmecbear
isol
coincid
increas
methicillin
resist
type
iv
sccmecbear
isol
involv
increas
methicillin
resist
belong
molecular
genotyp
genotyp
associ
predominantli
communityonset
diseas
rather
hospitalor
longtermcar
facilityonset
diseas
vs
vs
suggest
feral
descend
hospit
isol
longitudin
result
link
dramat
increas
mrsa
infect
expand
commun
reservoir
mrsa
genotyp
intrins
commun
surviv
advantag
outbreak
monkeypox
midwestern
unit
state
june
mark
first
document
human
infect
western
hemispher
consist
outbreak
africa
case
outbreak
associ
febril
rash
ill
describ
cluster
monkeypox
famili
spectrum
clinic
ill
includ
enceph
outlin
laboratori
confirm
monkeypox
method
standard
patient
inform
collect
questionnair
medic
chart
review
case
describ
laboratori
confirm
laboratori
method
includ
nucleic
acid
detect
viral
cultur
serolog
test
histopatholog
evalu
immunohistochem
test
result
famili
member
monkeypox
rash
ill
requir
hospit
sever
enceph
famili
member
mildest
clinic
cours
previous
receiv
smallpox
vaccin
diagnost
test
polymeras
chain
reaction
cultur
reveal
infecti
monkeypox
viru
skin
lesion
patient
patient
orthopoxviru
detect
immunohistochemistri
skin
lesion
patient
enceph
orthopoxvirusreact
immunoglobulin
igm
cerebrospin
fluid
patient
detect
igm
respons
orthopoxviru
antigen
conclus
patient
illustr
spectrum
clinic
ill
monkeypox
despit
common
sourc
exposur
manifest
sever
ill
may
affect
age
prior
smallpox
vaccin
report
monkeypox
addit
caus
febril
rash
ill
caus
sever
neurolog
infect
discuss
use
novel
laboratori
test
diagnosi
